Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Teva Terminates CureTech Agreements | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Teva Terminates CureTech Agreements

Ends investment in cancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva Pharmaceutical Industries has terminated its collaboration with CureTech, Ltd. The companies were working together on CT-011, a humanized monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. Teva entered into agreements with CureTech in 2006 and plans to book a noncash charge of $109 million as a result of the impairment of its investment in CureTech.
 
“We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the strategic decision to invest our resources elsewhere where we can have the most impact for patients,” said Dr. Michael Hayden, president and chief executive officer of R&D and chief R&D officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics